| Revenue growth | 21.9% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA margin improved 190 bps to 22.0%. |
| Demand visibility | Strong, targeting 8-9% IPM CAGR till FY30. |
| Management confidence | High, focused on '3C' philosophy and execution excellence. |
Growth
Revenue grew 21.9% YoY to INR 422.4 Cr; PAT increased 30.1% YoY to INR 60.1 Cr.
Outlook
Focusing on market share expansion in chronic segments and scaling the newly commercialized EU-GMP approved hormone facility.
Risks
Potential impacts from the Indian economy, international market volatility, and intense competition in the pharmaceutical industry.
Last quarter's promises, checked
Delivered
- Guided 15% revenue growth → delivered 21.9% (= BEAT)
- Guided 20% PAT growth → delivered 30.1% (= BEAT)
- Guided 80% gross margin → delivered 81.4% (= BEAT)
Partly delivered
- Guided 20% plus EBITDA margin → delivered 22.0% (= BEAT/PARTIAL as Q4 was 17.6%)
Investor Presentation filed with BSE, NSE: CORONA. Summary written with AI assistance from the document.
Corona Remedies Ltd: key numbers
- Share price
- ₹2,117.70
- Market cap
- ₹12,952 Cr
- Revenue (annual)
- ₹1,403 Cr
- Net profit (annual)
- ₹185.1 Cr
- P/E (TTM)
- 65.1×Sector 50.4×
- Promoter holding
- 69.00%+0.00% QoQ
- FII holding
- 3.63%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Corona Remedies Ltd
All →Corona Remedies Capital Structure Change
Sepia Investments Limited, Sage Investment Trust, and Anchor Partners sold 2,629,880 equity shares of Corona Remedies Limited. This non-promoter stake sale is disclosed under SEBI SAST regulations.
Corona Remedies Price Movement Clarification
CORONA Remedies Limited clarified that the recent increase in its share trading volume is purely market-driven and no undisclosed price-sensitive information exists.
Corona Remedies Earnings Call Transcript: Key Takeaways
Corona Remedies reported robust Q1 FY27 results with 21.9% revenue growth and 33.5% EBITDA growth. Strategy focuses on chronic therapies and scaling brand portfolios.
- Call
- Guides 20% growth
Corona Remedies Q1 FY27 Results: Net Profit ₹60.1 Cr, Up 30.1% YoY
Corona Remedies Ltd reported revenue from operations of ₹422.4 Cr (+21.9% YoY) and net profit of ₹60.1 Cr (+30.1% YoY) for Q1 FY27.
- Key figure
- Net profit ₹60.1 Cr · +30.1% YoY
Corona Remedies Earnings Call: Key Takeaways
Corona Remedies reported strong FY26 results, outperforming industry growth via specialty chronic segments and strategic acquisitions like Wokadine and the Bayer portfolio.
Corona Remedies Earnings Call: Key Takeaways
CORONA Remedies reported 17.3% FY26 revenue growth to ₹1,403.2 Cr, driven by chronic therapy focus and strategic acquisitions like Wokadine. Company maintain's 20.9% EBITDA margins.